Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8386 to 8400 of 8903 results

  1. Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (TA985)

    This guidance has been withdrawn because the simple discount patient access scheme for QuiremSpheres has been withdrawn.

    Withdrawn guidance

  2. Immunosuppressive therapy for renal transplantation in children and adolescents (TA99)

    This guidance has been updated and replaced by NICE technology appraisal guidance 482.

    Withdrawn guidance

  3. Lutonix drug-coated balloon for peripheral arterial disease (MIB72)

    NICE withdrew this medtech innovation briefing in October 2019 after the MHRA withdrew support for this type of technology being used in intermittent claudication for arterial disease.

    Withdrawn advice

  4. Ultroid 2.0 for internal haemorrhoids (MIB75)

    This medtech innovation briefing is temporarily unavailable, please contact mibs@nice.org.uk for further information.

    Withdrawn advice

  5. VitalPAC for assessing vital signs of patients in hospital (MIB79)

    This advice has been updated and replaced by NICE medtech innovation briefing 205.

    Withdrawn advice

  6. Zio Service for detecting cardiac arrhythmias (MIB101)

    This advice has been updated and replaced by NICE healthtech guidance 562.

    Withdrawn advice

  7. IQoro for stroke-related dysphagia (MIB175)

    September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.

    Withdrawn advice

  8. IQoro for hiatus hernia (MIB176)

    September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.

    Withdrawn advice

  9. PredictSure-IBD for inflammatory bowel disease prognosis (MIB178)

    This medtech innovation briefing has been updated and replaced by NICE medtech innovation briefing 313.

    Withdrawn advice

  10. Mepilex Border dressings for preventing pressure ulcers (MIB124)

    This advice has been updated and replaced by NICE medical technologies guidance 40.

    Withdrawn advice

  11. Promonitor for monitoring response to biologics in rheumatoid arthritis (MIB126)

    This advice has been replaced by NICE HealthTech guidance 521.

    Withdrawn advice

  12. Eyemax mono for age-related macular degeneration (MIB154)

    We’ve temporarily withdrawn this medtech innovation briefing to correct factual errors in the text.

    Withdrawn advice

  13. NephroCheck test to help assess the risk of acute kidney injury in critically ill patients (MIB156)

    This medtech innovation briefing has been updated and replaced by NICE HealthTech guidance 544.

    Withdrawn advice

  14. Rezum for treating benign prostatic hyperplasia (MIB158)

    This advice has been updated and replaced by NICE medical technologies guidance 49. 

    Withdrawn advice

  15. gammaCore for cluster headache (MIB162)

    This advice has been updated and replaced by NICE medical technologies guidance 46.

    Withdrawn advice